The purpose of this grant is to bring a variety of scientific disciplines to bear on a number of specific drug abuse problems. We propose to carry out major projects in the areas of chemical receptor probes, narcotic agonists and antagonists, the active principles of marihuana and methododlogy development. In the area of chemical receptor probes, we plan to synthesize specific compounds for studies of the postulated """"""""cough"""""""", PCP, sigma agonist, nicotine, and THC receptors. In the narcotic areas, we plan to extend our studies toward the elucidation of the """"""""cough"""""""" and sigma agonist receptors. We will continue to pharmacologically characterize opiate agonists and antagonists from our synthetic and drug abuse programs. Our studies with the cannabinoids will concentrate on assessing the dependence potential of Delta9-THC, the active principle of marihuana. We also plan to detemrine whether there are specific anatomical sites in the brain responsible for the typical behavioral effects of the cannabinoids. We plan to develop methods for better evaluating the rreinforcing efficacy of drugs of abuse. That is, why do some drugs act as more powerful reinforcers of behavior than others and what can we do to alter this? We will use cocaine as the first drug in these studies.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Project (R01)
Project #
5R01DA000490-12
Application #
3206770
Study Section
(SRCD)
Project Start
1973-06-01
Project End
1990-12-31
Budget Start
1987-01-01
Budget End
1987-12-31
Support Year
12
Fiscal Year
1987
Total Cost
Indirect Cost
Name
Virginia Commonwealth University
Department
Type
Overall Medical
DUNS #
City
Richmond
State
VA
Country
United States
Zip Code
23298
Kwilasz, Andrew J; Harris, Louis S; Vann, Robert E (2009) Removal of continuous nicotine infusion produces somatic but not behavioral signs of withdrawal in mice. Pharmacol Biochem Behav 94:114-8
Aceto, Mario D; May, Everette L; Harris, Louis S et al. (2007) Pharmacological studies with a nonpeptidic, delta-opioid (-)-(1R,5R,9R)-5,9-dimethyl-2'-hydroxy-2-(6-hydroxyhexyl)-6,7-benzomorphan hydrochloride ((-)-NIH 11082). Eur J Pharmacol 566:88-93